4D Molecular Therapeutics Files 8-K on Governance Changes
Ticker: FDMT · Form: 8-K · Filed: Jul 2, 2025 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-of-directors
TL;DR
4D Molecular Therapeutics filed an 8-K on 6/27/25 covering board changes and executive pay.
AI Summary
On June 27, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also announced other significant events impacting the company's operations and governance.
Why It Matters
This filing provides crucial updates on the company's leadership and compensation, which can influence investor confidence and strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate governance and compensation information, not indicating immediate operational or financial distress.
Key Numbers
- 001-39782 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-3506994 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — Registrant
- June 27, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Emeryville, California (location) — Principal Executive Offices
FAQ
What specific changes were made to the board of directors?
The filing indicates a departure of directors and the election of new directors, but the specific names and details are not provided in the provided text.
What are the key details regarding the compensatory arrangements of certain officers?
The filing mentions updates to compensatory arrangements for certain officers, but the specific details of these arrangements are not included in the provided text.
What other events are reported in this 8-K filing?
The filing indicates that 'Other Events' are also being reported, but the nature of these events is not specified in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 27, 2025.
What is the principal executive office address for 4D Molecular Therapeutics, Inc.?
The principal executive offices are located at 5858 Horton Street #455, Emeryville, California, 94608.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 2, 2025 regarding 4D Molecular Therapeutics, Inc. (FDMT).